In a 5 July warning letter to Outset Medical, the US Food and Drug Administration cited two concerns with the company’s Tablo Hemodialysis System, which is designed to treat kidney disease at home.
The agency’s first concern relates to materials on the company’s website that promote continuous renal replacement therapy (CRRT), a slower...